Get started
Work

107P Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study

Year: 2024
Type: article
Study design: Observational Study
Abstract: Metastatic non-clear cell renal cell carcinoma (mnccRCC) currently lacks standard first-line treatment options. This study evaluated the effectiveness and safety of ICI plus tyrosine kinase inhibitor (TKI) in mnccRCC patients through multi-center real-world evidence, encompassing the largest sample size to date.
DOI: 10.1016/j.iotech.2024.100850
Authors: Y. Peng, Z. Zhang, M. Chen, T. Jing, J. Huang, F. Zhou, P. Dong
Institutions: Sun Yat-sen University, Sun Yat-sen University Cancer Center, Central South University, Xiangya Hospital Central South University, First Affiliated Hospital Zhejiang University, Zhejiang University, Shanghai Jiao Tong University, Renji Hospital
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405375031
FWCI:
Cites:
Cited by:
Related to: 10